阻断T型钙通道可减轻早期糖尿病大鼠的蛋白尿和肾脏病理改变

被引：17

作者：

马骥

hotmail.com

张汝忠

hotmail.com

杨海春

hotmail.com

顾勇

hotmail.com

周江华

hotmail.com

林善锬

hotmail.com

机构：

[1] 上海医科大学华山医院肾脏科!

[2] Email:jima

[3] 上海医科大学华山医院肾脏

来源：

中华肾脏病杂志 | 2000年 / 02期

关键词：

钙通道; 糖尿病肾病; 大鼠;

D O I：

暂无

中图分类号：

R587.1 [糖尿病];

学科分类号：

100201 [内科学];

摘要：

目的探讨T型钙通道在实验性糖尿病肾病中的作用。方法采用单侧肾切除（UNx）的糖尿病大鼠模型，分别每日灌胃给予T型钙通道阻滞剂米贝地尔（Mib）、L型钙通道阻滞剂氨氯地平（Aml）、血管紧张素转换酶抑制剂西拉普利（Cil）、及Mib与Cil合用（M＋C），共4周，并使各药物处理组血压相近（每组n＝6～8）。结果Mib、Cil和M＋C治疗组较未治疗的糖尿病（DM）组尿白蛋白量明显减少（Mib：7．69±1．87，Cil：5.53±1．45，M＋C：3.87±0．88比DM：17．67±4．90，单位为μg／24h；P＜0．05），增高的Ccr下降。病理学检查显示Mib、Cil与M＋C组肾小球Ⅳ型胶原、层粘连蛋白显著少于DM。Aml对尿白蛋白量、肾小球基质和Ⅳ型胶原量无明显改善作用，但也可减少尿蛋白、Ccr和肾小球层粘连蛋白含量。M＋C治疗组的肾小球基质和Ⅳ型胶原量在各糖尿病大鼠中最低（均P＜0．05）。结论阻断T型钙通道可减轻糖尿病大鼠的蛋白尿和肾小球基质沉积，与ACE抑制剂合用有额外的保护效应，提示T型钙通道在糖尿病肾病中的作用不同于血管紧张素和L型钙通道，其机制有待进一步研究。

引用

页数：5

共 10 条

[1]

Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action[J] Zemin Cao;U Lennart Hulthén;Terri J. Allen;Mark E. Cooper Journal of Hypertension 1998,

[2]

Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats[J] Patrick Lacolley;Pierre Poitevin;Robert Koen;Bernard I. Levy Journal of Hypertension 1998,

[3]

Cardiovascular care with the new T-type calcium channel antagonist: Possible role of attendant sympathetic nervous system inhibition[J] Fritz R. Bühler Journal of Hypertension 1997,

[4]

Effects of calcium blockade on end-organ damage in experimental hypertension[J] Jo?l Ménard;Habib Karam;Murielle Véniant;Didier Heudes;Patrick Bruneval;Jean-Paul Clozel Journal of Hypertension 1997,

[5]

Renal protection in diabetes: an emerging role for calcium antagonists[J] Hans-Henrik Parving;Lise Tarnow;Peter Rossing Journal of Hypertension 1996,

[6]

Mibefradil; a Selective Calcium T-Channel Blocker; in Stroke-Prone Spontaneously Hypertensive Rats[J] Journal of Cardiovascular Pharmacology 1996,

[7]

Mibefradil Prevents Neointima Formation After Vascular Injury in Rats: Possible Role of the Blockade of the T-Type Voltage-Operated Calcium Channel[J] R. Schmitt;J.-P. Clozel;N. Iberg;F.R. Buhler Arteriosclerosis Thrombosis and Vascular Biology 1995,

[8]

Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): Effects on intracellular calcium and platelet aggregation[J] Martina Hahn;Vsevolod A. Tkachuk;Valery N. Bochkov;Ivan B. Cheglakov;Jean-Paul Clozel Cardiovascular Drugs and Therapy 1995,

[9]

Chronic Treatment with the CA<sup>2+</sup> Channel Inhibitor RO 40-5967 Potentiates Endothelium-Dependent Relaxations in the Aorta of the Hypertensive Salt Sensitive Dahl Rat[J] Chantal M. Boulanger;Barnabas Desta;Jean-Paul Clozel;Paul M. Vanhoutte Blood Pressure 1994,

[10]

Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers Kloke HJ; Branten AJ; Huysmans FT; et al; Kidney Int 1998,

← 1 →